Teva Pharmaceutical Industries Limited (TEVA) Financials

TEVA

FY2025 annual

Revenue $17.3B +4.3% YoY

Net Income $1.4B +186.0% YoY

EPS (Diluted) $1.21 +183.4% YoY

Free Cash Flow $1.1B +53.3% YoY

Market Cap $47.9B as of Oct 10, 2026

Price / Sales 3.4x on $14.1B revenue, trailing 12 months to June 30, 2026

Price / Earnings 34.0x on $1.4B net income, FY2025

Price / Book 6.2x on $7.8B equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Jul 29, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Jul 29, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the TEVA SEC filings page.

Teva Pharmaceutical Industries Limited (TEVA) reported $17.3B in revenue for fiscal year 2025, up 4.3% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI TEVA FY2025 2026-10-03

Teva’s 2025 rebound combined wider margins with stronger cash generation, but leverage and limited liquidity remain central to how it operates.

FY2024 paired a net loss of $1.64B with operating cash flow of $1.25B, indicating that non-cash charges and working-capital effects materially shaped reported earnings. FY2025 then paired net income of $1.41B with operating cash flow of $1.65B, bringing accounting profit and cash generation into closer alignment.

By FY2025, gross margin reached 51.8% and operating margin 12.5%, showing that more of each sales dollar survived both production and overhead. Operating margin had been negative in FY2024, so the rebound reflects a sharp reversal in cost absorption rather than a gradual trend.

Equity recovered to $7.91B in FY2025 from $5.37B in FY2024, partly restoring balance-sheet capacity after the prior loss. Yet debt-to-equity remained 4.2x while the current ratio was 1.0x, indicating financing remains heavily liability-based and short-term headroom is limited.

Financial Health Signals

Financial Health Score 34/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Teva Pharmaceutical Industries Limited's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Teva Pharmaceutical Industries Limited has an operating margin of 12.5%, meaning the company retains $13 of operating profit per $100 of revenue. This results in a moderate score of 41/100, indicating healthy but not exceptional operating efficiency. This is up from -1.8% the prior year.

Growth

Teva Pharmaceutical Industries Limited's revenue grew a modest 4.3% year-over-year to $17.3B. This slow but positive growth earns a score of 47/100.

Leverage

Teva Pharmaceutical Industries Limited has elevated debt relative to equity (D/E of 4.15), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 14/100, reflecting increased financial risk.

Liquidity

Teva Pharmaceutical Industries Limited's current ratio of 1.04 is below the typical benchmark, resulting in a score of 20/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Cash Flow

Teva Pharmaceutical Industries Limited has a free cash flow margin of 6.7%, earning a moderate score of 49/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns

Teva Pharmaceutical Industries Limited's ROE of 17.8% shows moderate profitability relative to equity, earning a score of 34/100. This is up from -30.5% the prior year.

Altman Z-Score Distress

1.02

Teva Pharmaceutical Industries Limited scores 1.02, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($47.9B) relative to total liabilities ($32.8B). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

7/8

Teva Pharmaceutical Industries Limited passes 7 of 8 computable financial strength tests (1 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

1.17x

For every $1 of reported earnings, Teva Pharmaceutical Industries Limited generates $1.17 in operating cash flow ($1.6B OCF vs $1.4B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Adequate

2.35x

Teva Pharmaceutical Industries Limited earns $2.35 in operating income for every $1 of interest expense ($2.2B vs $916.0M). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$4.1B

YoY-0.8%

QoQ+4.0%

5Y CAGR+1.2%

10Y CAGR-1.9%

Teva Pharmaceutical Industries Limited generated $4.1B in revenue in Q2 2026. This represents a decrease of 0.8% from the same quarter a year earlier. Against the prior quarter it is up 4.0%.

EBITDA

$10.0M

YoY-98.6%

QoQ-98.9%

Teva Pharmaceutical Industries Limited's EBITDA was $10.0M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 98.6% from the same quarter a year earlier. Against the prior quarter it is down 98.9%.

Net Income

-$576.0M

YoY-304.3%

QoQ-256.1%

Teva Pharmaceutical Industries Limited reported -$576.0M in net income in Q2 2026. This represents a decrease of 304.3% from the same quarter a year earlier. Against the prior quarter it is down 256.1%.

EPS (Diluted)

-$0.49

YoY-304.2%

QoQ-258.1%

Teva Pharmaceutical Industries Limited earned -$0.49 per diluted share (EPS) in Q2 2026. This represents a decrease of 304.2% from the same quarter a year earlier. Against the prior quarter it is down 258.1%.

Cash & Balance Sheet

Free Cash Flow

$307.0M

YoY+134.4%

QoQ+247.6%

5Y CAGR+23.9%

10Y CAGR-9.0%

Teva Pharmaceutical Industries Limited generated $307.0M in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 134.4% from the same quarter a year earlier. Against the prior quarter it is up 247.6%.

Cash & Debt

$3.7B

YoY+69.1%

QoQ-2.3%

5Y CAGR+8.5%

10Y CAGR-6.3%

Teva Pharmaceutical Industries Limited held $3.7B in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

1.17B

YoY+1.6%

QoQ+0.1%

5Y CAGR+1.1%

10Y CAGR+102.2%

Teva Pharmaceutical Industries Limited had 1.17B shares outstanding in Q2 2026. This represents an increase of 1.6% from the same quarter a year earlier. Against the prior quarter it is up 0.1%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

52.0%

YoY+1.6pp

QoQ+2.5pp

Teva Pharmaceutical Industries Limited's gross margin was 52.0% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 1.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.5 percentage points.

Operating Margin

-5.6%

YoY-16.5pp

QoQ-22.0pp

Teva Pharmaceutical Industries Limited's operating margin was -5.6% in Q2 2026, reflecting core business profitability. This is down 16.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 22.0 percentage points.

Net Margin

-13.9%

YoY-20.7pp

QoQ-23.2pp

Teva Pharmaceutical Industries Limited's net profit margin was -13.9% in Q2 2026, showing the share of revenue converted to profit. This is down 20.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 23.2 percentage points.

Return on Equity

-7.4%

YoY-11.6pp

QoQ-11.9pp

Teva Pharmaceutical Industries Limited's ROE was -7.4% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 11.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 11.9 percentage points.

Capital Allocation

R&D Spending

$970.0M

YoY+297.5%

QoQ+336.9%

Teva Pharmaceutical Industries Limited invested $970.0M in research and development in Q2 2026. This represents an increase of 297.5% from the same quarter a year earlier. Against the prior quarter it is up 336.9%.

Capital Expenditures

$104.0M

YoY+8.3%

QoQ-38.1%

5Y CAGR-1.6%

10Y CAGR-5.1%

Teva Pharmaceutical Industries Limited invested $104.0M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 8.3% from the same quarter a year earlier. Against the prior quarter it is down 38.1%.

Share Buybacks

Not reported for Q2 2026.

TEVA Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

TEVA quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$14.1B	$17.3B+4.3%	$16.5B+4.4%	$15.8B+6.2%	$14.9B-6.0%	$15.9B-4.7%	$16.7B-1.4%	$16.9B-7.6%	$18.3B-16.4%	$21.9B-0.2%	$21.9B+11.5%	$19.7B-3.1%	$20.3B-0.2%	$20.3B0.0%	$20.3B+10.9%	$18.3B
Cost of Revenue	N/A	$8.3B-1.9%	$8.5B+3.4%	$8.2B+3.1%	$8.0B-4.0%	$8.3B-7.3%	$8.9B-4.5%	$9.4B-6.3%	$10.0B-11.2%	$11.2B+11.9%	$10.0B+21.1%	$8.3B-10.0%	$9.2B-4.1%	$9.6B-0.6%	$9.7B+9.9%	$8.8B
Gross Profit	N/A	$8.9B+10.8%	$8.1B+5.5%	$7.6B+9.6%	$7.0B-8.2%	$7.6B-1.7%	$7.7B+2.5%	$7.5B-9.1%	$8.3B-21.8%	$10.6B-10.5%	$11.9B+4.4%	$11.4B+2.7%	$11.1B+3.3%	$10.7B+0.5%	$10.7B+11.9%	$9.5B
R&D Expenses	N/A	$1.0B+1.5%	$998.0M+4.7%	$953.0M+872.4%	$98.0M-89.9%	$967.0M-3.0%	$997.0M-1.3%	$1.0B+786.0%	$114.0M-34.9%	$175.0M-58.5%	$422.0M+1105.7%	$35.0M	$0-100.0%	$5.0M-93.2%	$73.0M+386.7%	$15.0M
SG&A Expenses	N/A	$1.3B+10.9%	$1.2B-0.1%	$1.2B-1.5%	$1.2B+7.4%	$1.1B-6.3%	$1.2B-1.6%	$1.2B-8.2%	$1.3B-10.5%	$1.5B+12.9%	$1.3B-5.5%	$1.4B+11.8%	$1.2B-1.8%	$1.2B+0.1%	$1.2B+32.8%	$932.0M
Operating Income	N/A	$2.2B+811.9%	-$303.0M-170.0%	$433.0M+119.7%	-$2.2B-228.0%	$1.7B+148.0%	-$3.6B-706.3%	-$443.0M+72.9%	-$1.6B+90.6%	-$17.5B-911.7%	$2.2B-35.7%	$3.4B-15.2%	$4.0B+139.6%	$1.6B-25.2%	$2.2B-29.1%	$3.1B
EBITDA	N/A	$3.2B+317.9%	$756.0M-52.3%	$1.6B+278.4%	-$889.0M-129.2%	$3.0B+251.2%	-$2.0B-257.5%	$1.3B+523.9%	$205.0M+101.3%	-$15.4B-517.9%	$3.7B-21.1%	$4.7B-14.6%	$5.5B+65.9%	$3.3B-15.9%	$3.9B-6.3%	$4.2B
Interest Expense	N/A	$916.0M-8.6%	$1.0B-2.6%	$1.0B+10.6%	$930.0M+4.4%	$891.0M-1.1%	$901.0M+9.6%	$822.0M-10.7%	$920.0M+5.1%	$875.0M+60.3%	$546.0M+102.2%	$270.0M-10.0%	$300.0M-4.5%	$314.0M-11.5%	$355.0M+51.7%	$234.0M
Income Tax	N/A	-$180.0M-126.6%	$676.0M+9757.1%	-$7.0M+98.9%	-$643.0M-404.7%	$211.0M+225.6%	-$168.0M+39.6%	-$278.0M-42.6%	-$195.0M+89.9%	-$1.9B-471.0%	$521.0M-17.8%	$634.0M+7.3%	$591.0M+1474.4%	-$43.0M+68.6%	-$137.0M-207.9%	$127.0M
Net Income	N/A	$1.4B+186.0%	-$1.6B-193.2%	-$559.0M+77.1%	-$2.4B-686.6%	$417.0M+110.5%	-$4.0B-299.4%	-$999.0M+53.5%	-$2.1B+86.8%	-$16.3B-5043.8%	$329.0M-79.3%	$1.6B-48.0%	$3.1B+140.7%	$1.3B-35.4%	$2.0B-28.9%	$2.8B
EPS (Basic)	N/A	$1.23+184.8%	-$1.45-190.0%	-$0.50+77.3%	-$2.20-678.9%	$0.38+110.4%	-$3.64-300.0%	-$0.91+61.3%	-$2.35+85.5%	-$16.26-23328.6%	$0.07-96.2%	$1.84-48.6%	$3.58+140.3%	$1.49-33.8%	$2.25-27.4%	$3.10
EPS (Diluted)	$0.60	$1.21+183.4%	-$1.45-190.0%	-$0.50+77.3%	-$2.20-678.9%	$0.38+110.4%	-$3.64-300.0%	-$0.91+61.3%	-$2.35+85.5%	-$16.26	$0.07	$1.82-48.9%	$3.56+138.9%	$1.49-33.8%	$2.25-27.2%	$3.09
Diluted Shares (Avg)	N/A	1.16B+2.8%	1.13B+1.1%	1.12B+0.8%	1.11B+0.3%	1.11B+1.1%	1.09B+0.4%	1.09B+6.9%	1.02B+0.5%	1.02B	961M	864M+0.7%	858M+0.9%	850M-2.6%	873M-2.2%	893M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$4.1B-0.8%	$4.0B+2.3%	$1.5B-64.5%	$4.5B+3.4%	$4.2B+0.3%	$3.9B+1.9%	$4.2B-5.1%	$4.3B+12.5%
Cost of Revenue	$2.0B-4.1%	$2.0B-0.1%	N/A	$2.2B-0.3%	$2.1B-3.1%	$2.0B-1.7%	$2.1B+3.4%	$2.2B+9.2%
Gross Profit	$2.2B+2.4%	$2.0B+5.1%	N/A	$2.3B+7.3%	$2.1B+3.9%	$1.9B+6.0%	$2.1B-12.2%	$2.1B+16.0%
R&D Expenses	$970.0M+297.5%	$222.0M-10.1%	N/A	$256.0M+6.7%	$244.0M-9.3%	$247.0M+2.1%	$247.0M+9.3%	$240.0M-5.1%
SG&A Expenses	$317.0M+3.9%	$304.0M+2.4%	N/A	$317.0M+6.4%	$305.0M+7.8%	$297.0M+6.8%	$302.0M+3.8%	$298.0M+11.2%
Operating Income	-$231.0M-150.8%	$652.0M+25.6%	N/A	$882.0M+1829.4%	$455.0M+9200.0%	$519.0M+338.1%	-$29.0M-103.8%	-$51.0M-114.8%
EBITDA	$10.0M-98.6%	$891.0M+16.8%	N/A	$1.1B+443.8%	$706.0M+178.0%	$763.0M+1313.0%	$240.0M-76.5%	$208.0M-66.8%
Income Tax	$121.0M+255.1%	$67.0M-9.5%	N/A	$214.0M+210.1%	-$78.0M-112.4%	$74.0M+242.3%	$29.0M-27.5%	$69.0M+675.0%
Net Income	-$576.0M-304.3%	$369.0M+72.4%	N/A	$433.0M+199.1%	$282.0M+133.3%	$214.0M+254.0%	-$217.0M-146.8%	-$437.0M-733.3%
EPS (Basic)	-$0.49-296.0%	$0.32+68.4%	$0.42+321.1%	$0.38+197.4%	$0.25+133.3%	$0.19+258.3%	-$0.19-146.3%	-$0.39-750.0%
EPS (Diluted)	-$0.49-304.2%	$0.31+72.2%	$0.41+315.8%	$0.37+194.9%	$0.24+132.0%	$0.18+250.0%	-$0.19-146.3%	-$0.39-750.0%
Diluted Shares (Avg)	1.17B+0.3%	1.18B+1.7%	N/A	1.16B+2.7%	1.16B+2.5%	1.16B+3.2%	N/A	1.13B-0.2%

Not reported in any period shown, so not listed: Interest Expense.

TEVA Balance Sheet

TEVA quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$40.7B+3.6%	$39.3B-9.6%	$43.5B-1.2%	$44.0B-7.7%	$47.7B-5.9%	$50.6B-11.9%	$57.5B-5.3%	$60.7B-14.1%	$70.6B-24.1%	$93.1B+71.6%	$54.2B+16.8%	$46.4B-2.3%	$47.5B-6.1%	$50.6B+0.9%	$50.1B
Current Assets	$13.9B+11.1%	$12.6B+0.5%	$12.5B+3.6%	$12.1B-4.2%	$12.6B-3.3%	$13.0B-3.4%	$13.5B-2.4%	$13.8B-10.3%	$15.4B-10.7%	$17.2B-6.4%	$18.4B+27.8%	$14.4B+4.9%	$13.7B-16.1%	$16.4B+13.2%	$14.5B
Cash & Equivalents	$3.6B+7.8%	$3.3B+2.3%	$3.2B+15.2%	$2.8B+29.4%	$2.2B-0.6%	$2.2B+10.2%	$2.0B+10.8%	$1.8B+85.0%	$963.0M-2.5%	$988.0M-85.8%	$6.9B+212.0%	$2.2B+114.5%	$1.0B-63.9%	$2.9B+162.7%	$1.1B
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$3.2B+5.7%	$3.0B-25.2%	$4.0B+4.9%	$3.8B+0.4%	$3.8B-13.3%	$4.4B-0.4%	$4.4B-6.5%	$4.7B-3.9%	$4.9B-0.6%	$5.0B+24.9%	$4.0B-9.3%	$4.4B-13.5%	$5.1B-8.2%	$5.5B+9.8%	$5.0B
Accounts Receivable	$3.7B+21.2%	$3.1B-10.2%	$3.4B-7.8%	$3.7B-18.4%	$4.5B-1.1%	$4.6B-19.3%	$5.7B-2.5%	$5.8B-18.3%	$7.1B-5.3%	$7.5B+40.6%	$5.3B-1.1%	$5.4B+1.3%	$5.3B-4.2%	$5.6B-10.3%	$6.2B
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$16.0B0.0%	$16.0B-6.9%	$17.2B0.0%	$17.2B-2.6%	$17.6B-14.5%	$20.6B-17.0%	$24.8B-0.3%	$24.9B-12.3%	$28.4B-36.0%	$44.4B+133.4%	$19.0B+3.4%	$18.4B-3.0%	$19.0B+0.7%	$18.9B+3.1%	$18.3B
Total Liabilities	$32.8B-2.3%	$33.6B-4.9%	$35.4B-0.2%	$35.4B-2.8%	$36.4B-8.0%	$39.6B-6.7%	$42.4B-5.5%	$44.9B-13.5%	$51.9B-10.7%	$58.1B+138.9%	$24.3B+5.4%	$23.1B-7.3%	$24.9B-10.3%	$27.7B-0.2%	$27.8B
Current Liabilities	$13.5B+5.2%	$12.8B+4.5%	$12.2B+6.8%	$11.5B+4.0%	$11.0B-16.2%	$13.2B-3.7%	$13.7B-4.5%	$14.3B-20.1%	$17.9B-3.1%	$18.5B+42.2%	$13.0B+5.8%	$12.3B+2.7%	$12.0B-7.2%	$12.9B-5.8%	$13.7B
Non-Current Liabilities	$19.4B-6.9%	$20.8B-9.9%	$23.1B-3.5%	$23.9B-5.7%	$25.4B-3.9%	$26.4B-8.1%	$28.7B-6.0%	$30.6B-10.0%	$33.9B-14.2%	$39.6B+250.2%	$11.3B+4.9%	$10.8B-16.5%	$12.9B-13.1%	$14.9B+5.2%	$14.1B
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$28.8B-11.4%	$32.5B+289.1%	$8.4B-2.4%	$8.6B-23.5%	$11.2B-20.8%	$14.1B+24.1%	$11.4B
Total Equity	$7.9B+47.2%	$5.4B-28.4%	$7.5B-3.8%	$7.8B-24.1%	$10.3B+2.5%	$10.0B-28.2%	$14.0B-5.0%	$14.7B-15.3%	$17.4B-47.9%	$33.3B+12.0%	$29.8B+27.7%	$23.3B+3.3%	$22.6B-0.9%	$22.8B+2.6%	$22.2B
Retained Earnings	-$13.8B+9.3%	-$15.2B-12.1%	-$13.5B-4.3%	-$13.0B-23.2%	-$10.5B+3.8%	-$10.9B-57.4%	-$7.0B-16.8%	-$6.0B-56.7%	-$3.8B-127.9%	$13.6B-8.4%	$14.9B+2.9%	$14.4B+15.2%	$12.5B+1.5%	$12.3B+9.4%	$11.3B

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$39.9B-0.7%	$40.0B+4.2%	$40.7B+3.6%	$39.9B-4.6%	$40.1B-2.9%	$38.4B-10.2%	$39.3B-9.6%	$41.8B-0.8%
Current Assets	$13.8B+9.0%	$13.7B+18.9%	$13.9B+11.1%	$12.7B+3.4%	$12.6B+8.5%	$11.5B-6.3%	$12.6B+0.5%	$12.3B+7.8%
Cash & Equivalents	$3.7B+69.1%	$3.7B+120.4%	$3.6B+7.8%	$2.2B-33.6%	$2.2B-4.3%	$1.7B-43.3%	$3.3B+2.3%	$3.3B+47.6%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$3.2B-7.9%	$3.2B-2.2%	$3.2B+5.7%	$3.3B-16.1%	$3.5B-10.9%	$3.2B-17.8%	$3.0B-25.2%	$4.0B-2.3%
Accounts Receivable	$3.5B-2.0%	$3.4B+0.3%	$3.7B+21.2%	$3.8B+10.1%	$3.6B-5.4%	$3.4B-2.1%	$3.1B-10.2%	$3.5B+2.3%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$15.8B-0.7%	$15.8B+2.2%	$16.0B0.0%	$15.9B-1.1%	$15.9B-3.3%	$15.5B-9.0%	$16.0B-6.9%	$16.1B-4.5%
Total Liabilities	$32.1B-3.6%	$31.8B-1.0%	$32.8B-2.3%	$32.6B-7.8%	$33.3B-4.2%	$32.1B-8.8%	$33.6B-4.9%	$35.4B+1.9%
Current Liabilities	$15.6B+31.9%	$13.5B+21.3%	$13.5B+5.2%	$11.5B-16.7%	$11.9B-9.0%	$11.2B-19.1%	$12.8B+4.5%	$13.8B+21.1%
Non-Current Liabilities	$16.5B-23.2%	$18.3B-12.9%	$19.4B-6.9%	$21.1B-2.2%	$21.4B-1.4%	$21.0B-2.1%	$20.8B-9.9%	$21.6B-7.4%
Total Equity	$7.8B+13.6%	$8.2B+31.4%	$7.9B+47.2%	$7.3B+19.5%	$6.8B+7.4%	$6.3B-14.0%	$5.4B-28.4%	$6.1B-12.5%
Retained Earnings	-$14.0B+4.8%	-$13.4B+10.5%	-$13.8B+9.3%	-$14.2B+4.8%	-$14.7B-1.1%	-$15.0B-9.4%	-$15.2B-12.1%	-$15.0B-6.9%

Not reported in any period shown, so not listed: Long-Term Debt.

TEVA Cash Flow Statement

TEVA quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$1.9B	$1.6B+32.2%	$1.2B-8.8%	$1.4B-14.0%	$1.6B+99.2%	$798.0M-34.4%	$1.2B+62.6%	$748.0M-69.4%	$2.4B+9.9%	$2.2B-57.4%	$5.2B-5.7%	$5.5B+8.1%	$5.1B+58.4%	$3.2B-29.2%	$4.6B+10.6%	$4.1B
Depreciation & Amortization	N/A	$1.0B-5.4%	$1.1B-8.2%	$1.2B-11.9%	$1.3B-1.7%	$1.3B-14.6%	$1.6B-9.6%	$1.7B-6.5%	$1.8B-12.8%	$2.1B+38.6%	$1.5B+16.5%	$1.3B-13.3%	$1.5B-8.2%	$1.6B-3.9%	$1.7B+59.8%	$1.1B
Stock-Based Compensation	N/A	$157.0M+27.6%	$123.0M+1.7%	$121.0M-2.4%	$124.0M+4.2%	$119.0M-7.8%	$129.0M+8.4%	$119.0M-23.2%	$155.0M+16.5%	$133.0M+7.3%	$124.0M+6.0%	$117.0M+23.2%	$95.0M+48.4%	$64.0M-22.0%	$82.0M-9.9%	$91.0M
Capital Expenditures	$550.0M	$501.0M+0.6%	$498.0M-5.3%	$526.0M-4.0%	$548.0M-2.5%	$562.0M-2.8%	$578.0M+10.1%	$525.0M-19.4%	$651.0M-25.5%	$874.0M-3.0%	$901.0M+16.7%	$772.0M-16.9%	$929.0M-9.9%	$1.0B-6.6%	$1.1B+4.8%	$1.1B
Free Cash Flow	$1.3B	$1.1B+53.3%	$749.0M-11.0%	$842.0M-19.2%	$1.0B+341.5%	$236.0M-63.0%	$638.0M+186.1%	$223.0M-87.6%	$1.8B+32.9%	$1.4B-68.8%	$4.3B-9.4%	$4.8B+13.6%	$4.2B+90.3%	$2.2B-36.4%	$3.5B+12.6%	$3.1B
Investing Cash Flow	$38.0M	$737.0M-6.9%	$792.0M-18.2%	$968.0M+47.6%	$656.0M-56.9%	$1.5B+76.5%	$863.0M-36.3%	$1.4B-27.4%	$1.9B-45.9%	$3.4B+109.6%	-$35.7B-542.2%	-$5.6B-283.8%	-$1.4B-26.4%	-$1.1B-1.1%	-$1.1B+85.1%	-$7.6B
Financing Cash Flow	-$401.0M	-$2.2B-20.1%	-$1.8B+6.4%	-$1.9B-28.6%	-$1.5B+31.5%	-$2.2B-15.2%	-$1.9B+2.1%	-$1.9B+42.5%	-$3.4B+41.7%	-$5.8B-122.8%	$25.2B+424.8%	$4.8B+302.3%	-$2.4B+38.8%	-$3.9B-131.4%	-$1.7B-150.3%	$3.3B
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$12.0M-98.7%	$901.0M-30.9%	$1.3B+12.8%	$1.2B-0.1%	$1.2B+6.2%	$1.1B+27.4%	$855.0M+6.9%	$800.0M
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0-100.0%	$439.0M-12.2%	$500.0M+0.6%	$497.0M-57.2%	$1.2B+29.1%	$899.0M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$411.0M+81.1%	-$40.0M+61.9%	$1.2B+101.4%	$369.0M-46.8%	$227.0M+120.4%	-$105.0M+15.3%	$575.0M-51.4%	$693.0M+13760.0%
Depreciation & Amortization	$241.0M-4.0%	$239.0M-2.0%	$260.0M-3.3%	$249.0M-3.9%	$251.0M-3.1%	$244.0M-10.3%	$269.0M+1.1%	$259.0M-8.5%
Stock-Based Compensation	$40.0M+5.3%	$43.0M+26.5%	N/A	$34.0M+17.2%	$38.0M+18.8%	$34.0M+21.4%	N/A	$29.0M-6.5%
Capital Expenditures	$104.0M+8.3%	$168.0M+32.3%	$142.0M+10.1%	$136.0M-8.1%	$96.0M-1.0%	$127.0M+2.4%	$129.0M+8.4%	$148.0M-0.7%
Free Cash Flow	$307.0M+134.4%	-$208.0M+10.3%	$1.0B+127.8%	$233.0M-57.2%	$131.0M+2083.3%	-$232.0M+6.5%	$446.0M-58.1%	$545.0M+478.5%
Investing Cash Flow	-$491.0M-308.1%	$229.0M+13.9%	$165.0M-18.3%	$135.0M-49.6%	$236.0M+32.6%	$201.0M+39.6%	$202.0M-32.9%	$268.0M+45.7%
Financing Cash Flow	-$1.0M-116.7%	$13.0M+100.7%	$40.0M+105.9%	-$453.0M	$6.0M+100.6%	-$1.7B-1055.0%	-$674.0M-17.0%	$0+100.0%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

TEVA Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

TEVA quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	51.8%+3.1pp	48.7%+0.5pp	48.3%+1.5pp	46.7%-1.1pp	47.8%+1.5pp	46.4%+1.8pp	44.6%-0.8pp	45.4%-3.2pp	48.6%-5.6pp	54.1%-3.6pp	57.8%+3.2pp	54.5%+1.8pp	52.7%+0.3pp	52.4%+0.5pp	52.0%
Operating Margin	12.5%+14.3pp	-1.8%-4.6pp	2.7%+17.4pp	-14.7%-25.5pp	10.8%+32.3pp	-21.4%-18.8pp	-2.6%+6.3pp	-9.0%+71.0pp	-80.0%-89.8pp	9.8%-7.2pp	17.1%-2.4pp	19.5%+11.4pp	8.1%-2.7pp	10.8%-6.1pp	17.0%
Net Margin	8.2%+18.1pp	-9.9%-6.4pp	-3.5%+12.9pp	-16.4%-19.0pp	2.6%+26.6pp	-23.9%-18.0pp	-5.9%+5.8pp	-11.8%+62.7pp	-74.4%-75.9pp	1.5%-6.6pp	8.1%-7.0pp	15.1%+8.8pp	6.3%-3.4pp	9.7%-5.4pp	15.1%
Return on Equity	17.8%+48.3pp	-30.5%-23.0pp	-7.4%+23.9pp	-31.3%-35.4pp	4.1%+43.9pp	-39.8%-32.6pp	-7.1%+7.5pp	-14.6%+79.1pp	-93.7%-94.7pp	1.0%-4.3pp	5.3%-7.8pp	13.1%+7.5pp	5.6%-3.0pp	8.6%-3.8pp	12.4%
Return on Assets	3.5%+7.6pp	-4.2%-2.9pp	-1.3%+4.3pp	-5.6%-6.4pp	0.9%+8.8pp	-7.9%-6.1pp	-1.7%+1.8pp	-3.5%+19.5pp	-23.0%-23.4pp	0.4%-2.6pp	2.9%-3.6pp	6.6%+3.9pp	2.7%-1.2pp	3.9%-1.6pp	5.5%
Current Ratio	1.04+0.1x	0.980.0x	1.020.0x	1.05-0.1x	1.14+0.2x	0.990.0x	0.980.0x	0.96+0.1x	0.86-0.1x	0.93-0.5x	1.41+0.2x	1.170.0x	1.15-0.1x	1.27+0.2x	1.06
Debt-to-Equity	4.15-2.1x	6.25+1.5x	4.71+0.2x	4.54+1.0x	3.54-0.4x	3.95+0.9x	3.040.0x	3.05+1.4x	1.66+0.7x	0.98+0.7x	0.28-0.1x	0.37-0.1x	0.50-0.1x	0.62+0.1x	0.51
Asset Turnover	0.420.0x	0.42+0.1x	0.360.0x	0.340.0x	0.330.0x	0.330.0x	0.290.0x	0.300.0x	0.31+0.1x	0.24-0.1x	0.36-0.1x	0.440.0x	0.430.0x	0.400.0x	0.37
FCF Margin	6.7%+2.1pp	4.5%-0.8pp	5.3%-1.7pp	7.0%+5.5pp	1.5%-2.3pp	3.8%+2.5pp	1.3%-8.5pp	9.8%+3.6pp	6.2%-13.6pp	19.7%-4.5pp	24.3%+3.6pp	20.7%+9.8pp	10.9%-6.2pp	17.1%+0.2pp	16.8%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	52.0%+1.6pp	49.5%+1.3pp	N/A	51.4%+1.8pp	50.3%+1.7pp	48.2%+1.9pp	50.1%-4.1pp	49.6%+1.5pp
Operating Margin	-5.6%-16.5pp	16.4%+3.0pp	N/A	19.7%+20.9pp	10.9%+11.0pp	13.3%+19.1pp	-0.7%-17.6pp	-1.2%-10.1pp
Net Margin	-13.9%-20.7pp	9.3%+3.8pp	N/A	9.7%+19.8pp	6.8%+27.1pp	5.5%+9.1pp	-5.1%-15.5pp	-10.1%-11.9pp
Return on Equity	-7.4%-11.6pp	4.5%+1.1pp	N/A	6.0%+13.2pp	4.1%+17.4pp	3.4%+5.3pp	-4.0%-10.2pp	-7.2%-8.2pp
Return on Assets	-1.5%-2.2pp	0.9%+0.4pp	N/A	1.1%+2.1pp	0.7%+2.8pp	0.6%+0.9pp	-0.5%-1.6pp	-1.1%-1.2pp
Current Ratio	0.88-0.2x	1.010.0x	1.04+0.1x	1.11+0.2x	1.06+0.2x	1.03+0.1x	0.980.0x	0.89-0.1x
Debt-to-Equity	4.14-0.7x	3.87-1.3x	4.15-2.1x	4.50-1.3x	4.88-0.6x	5.13+0.3x	6.25+1.5x	5.83+0.8x
Asset Turnover	0.100.0x	0.100.0x	0.04-0.1x	0.110.0x	0.100.0x	0.100.0x	0.110.0x	0.100.0x
FCF Margin	7.4%+4.3pp	-5.2%+0.7pp	67.7%+57.2pp	5.2%-7.4pp	3.1%+3.0pp	-6.0%+0.5pp	10.5%-13.3pp	12.6%+16.3pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Teva Pharmaceutical Industries Limited TEVA	FY2025	$17.3B	$1.4B	8.2%	$47.9B	34/100
United Therapeutics Corp UTHR	FY2025	$3.2B	$1.3B	41.9%	$23.6B	88/100
Viatris Inc. VTRS	FY2025	$14.3B	-$3.5B	-24.6%	$20.3B	28/100
Dr. Reddy's Laboratories Limited RDY	FY2026	$3.6B	$452.0M	12.6%	$10.4B	36/100
Neurocrine Biosciences Inc NBIX	FY2025	$2.9B	$478.6M	16.7%	$14.5B	80/100

Where Teva Pharmaceutical Industries Limited Ranks

Frequently Asked Questions

What is Teva Pharmaceutical Industries Limited's annual revenue?

Teva Pharmaceutical Industries Limited (TEVA) reported $17.3B in total revenue for fiscal year 2025. This represents a 4.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Teva Pharmaceutical Industries Limited's revenue growing?

Teva Pharmaceutical Industries Limited (TEVA) revenue grew by 4.3% year-over-year, from $16.5B to $17.3B in fiscal year 2025.

Is Teva Pharmaceutical Industries Limited profitable?

Yes, Teva Pharmaceutical Industries Limited (TEVA) reported a net income of $1.4B in fiscal year 2025, with a net profit margin of 8.2%.

What is Teva Pharmaceutical Industries Limited's EBITDA?

Teva Pharmaceutical Industries Limited (TEVA) had EBITDA of $3.2B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Teva Pharmaceutical Industries Limited's gross margin?

Teva Pharmaceutical Industries Limited (TEVA) had a gross margin of 51.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Teva Pharmaceutical Industries Limited's operating margin?

Teva Pharmaceutical Industries Limited (TEVA) had an operating margin of 12.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Teva Pharmaceutical Industries Limited's net profit margin?

Teva Pharmaceutical Industries Limited (TEVA) had a net profit margin of 8.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Teva Pharmaceutical Industries Limited's return on equity (ROE)?

Teva Pharmaceutical Industries Limited (TEVA) has a return on equity of 17.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Teva Pharmaceutical Industries Limited's free cash flow?

Teva Pharmaceutical Industries Limited (TEVA) generated $1.1B in free cash flow during fiscal year 2025. This represents a 53.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Teva Pharmaceutical Industries Limited's operating cash flow?

Teva Pharmaceutical Industries Limited (TEVA) generated $1.6B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Teva Pharmaceutical Industries Limited's total assets?

Teva Pharmaceutical Industries Limited (TEVA) had $40.7B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Teva Pharmaceutical Industries Limited's capital expenditures?

Teva Pharmaceutical Industries Limited (TEVA) invested $501.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Teva Pharmaceutical Industries Limited spend on research and development?

Teva Pharmaceutical Industries Limited (TEVA) invested $1.0B in research and development during fiscal year 2025.

How many shares does Teva Pharmaceutical Industries Limited have outstanding?

Teva Pharmaceutical Industries Limited (TEVA) had 1.15B shares outstanding as of fiscal year 2025.

What is Teva Pharmaceutical Industries Limited's current ratio?

Teva Pharmaceutical Industries Limited (TEVA) had a current ratio of 1.04 as of fiscal year 2025, which is considered adequate.

What is Teva Pharmaceutical Industries Limited's debt-to-equity ratio?

Teva Pharmaceutical Industries Limited (TEVA) had a debt-to-equity ratio of 4.15 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Teva Pharmaceutical Industries Limited's return on assets (ROA)?

Teva Pharmaceutical Industries Limited (TEVA) had a return on assets of 3.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Teva Pharmaceutical Industries Limited's P/E ratio?

Teva Pharmaceutical Industries Limited (TEVA) trades at 34.0x earnings, its market capitalization divided by net income of $1.4B net income, FY2025. The market capitalization is $47.9B as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Teva Pharmaceutical Industries Limited's price-to-sales ratio?

Teva Pharmaceutical Industries Limited (TEVA) trades at 3.4x sales, its market capitalization divided by revenue of $14.1B revenue, trailing 12 months to June 30, 2026. The market capitalization is $47.9B as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Teva Pharmaceutical Industries Limited's Altman Z-Score?

Teva Pharmaceutical Industries Limited (TEVA) has an Altman Z-Score of 1.02, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Teva Pharmaceutical Industries Limited's Piotroski F-Score?

Teva Pharmaceutical Industries Limited (TEVA) has a Piotroski F-Score of 7 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Teva Pharmaceutical Industries Limited's earnings high quality?

Teva Pharmaceutical Industries Limited (TEVA) has an earnings quality ratio of 1.17x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Teva Pharmaceutical Industries Limited cover its interest payments?

Teva Pharmaceutical Industries Limited (TEVA) has an interest coverage ratio of 2.35x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Teva Pharmaceutical Industries Limited?

Teva Pharmaceutical Industries Limited (TEVA) scores 34 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.